cronos group glp-1 receptor agonists weight management diabetes treatments Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 | Advances in Therapy Frontiers | Exploring the multifaceted

To reduce these side effects, moderation is key

The market also sees significant opportunities for expanding the application of GLP-1 receptor agonists beyond diabetes, with emerging research exploring their role in treating heart failure, non-alcoholic steatohepatitis (NASH), and other chronic conditions

The Big Trial of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events Presented at the American Heart Association and simultaneously published in NEJM today is the trial of over 17,600 patients who were randomly assigned either the GLP-1 semaglutide (a glucagon-like peptide-1 receptor agonist) or placebo and were followed for well over 3 years

Murray CD, Martin NM, Patterson M, et al

GLP-1 Receptor Agonists vs